Randomized Controlled Trials as Topic
FDA Signals Higher Efficacy Bar for New CAR‑T Cancer Therapies
FDA; CAR-T; chimeric antigen receptor T-cell therapy; oncology; regulatory standards; superiority trials; randomized controlled trials; overall survival; hematologic malignancies; cell and gene therapy